“…We read with great interest the commentary by Restrepo et al 1 discussing our Pennsylvania multicenter postmarket experience with the Flow Redirection Endoluminal Device (FRED) (MicroVention Inc). 2 We thank the authors for their interest and the editor for the opportunity to respond.…”